Online Inquiry

For Research Use Only. Not For Clinical Use.

Contact Us
  • Email:

Reprogramming Factors

Overview Our Service Applications FAQs Scientific Resources Related Services

With years of experience in neuroscience and our most devoted scientists, Creative Biolabs is your reliable partner to provide high-quality and customized reprogramming factors for your neuroscience research.

Reprogramming and Reprogramming Factors for Development of Cell Models

During the decades since its birth, iPSC technology has already shown potential for clinical applications and disease modeling. Therefore, deriving high-quality, comprehensively characterized iPSC in a scalable process is crucial for their use in translational applications. Ever since work on pluripotency induction was originally published, reporting the reprogramming of somatic cells to iPSCs by the ectopic expression of the transcription factors, high expectations regarding their potential use for regenerative medicine have emerged.

Reprogramming is initiated by changes in the chromatin structure and transcriptome of a differentiated state into a pluripotent-like state. The reprogramming factors spontaneously bind together to form an interconnected autoregulatory circuitry, triggering their core promoter genes and cooperating with other pluripotency-associated genes. Reprogramming aims to generate pluripotent cells from any cell that can be isolated from a patient, partially erase the somatic epigenetic program, and reactivate the machinery involved in pluripotency.

Reprograming Methods

Many methods for generating integration-free iPSCs have been developed that involve the transient expression of reprogramming factors (such as Oct4, Sox2, Klf4, and c-Myc), including adenoviruses plasmids, transposons, Sendai viruses, synthetic mRNAs, and recombinant proteins. Due to its reliability and high efficiency, retrovirus-mediated transduction remains the most widely used method for delivering reprogramming factors. Genes coding for reprogramming factors delivered in this way is randomly and stably integrated into the genome and affect the process, the differentiation of iPSCs into mature cell types, and variability between different iPSCs lines from a single patient.

Mechanistic insights into transcription factor-mediated reprogramming towards pluripotency. Fig.1 Illustration of the wave models of reprogramming.1

Services at Creative Biolabs

The generation of iPSCs from differentiated mature cells is one of the most promising approaches in stem cell-based models and regenerative medicine. Somatic cells can revert to the pluripotent state through the expression of specific reprogramming factors. The identification and study of these factors have helped to provide insight into the mechanism of induced pluripotency. As a top-ranking provider in the neuroscience market, Creative Biolabs offers various research tools to deal with the urgent demands for your neuroscience research and cell model development. With years of experience and our most devoted scientists, we are confident to tailor the reprogramming factors production to meet your specific requirements.

Discoveries of somatic cell reprogramming have opened the possibility of creating iPSCs using innovative strategies. Creative Biolabs is your trusted partner to offer the custom production of reprogramming factors for our global clients. Please contact us for more information and a detailed quote. We look forward to discussing your inquiry and finding the best solution for your needs.

In addition to production, we provide comprehensive support services, including technical assistance, quality control testing, and ongoing maintenance to ensure the long-term viability and effectiveness of our reprogramming factors. Our goal is to provide neuroscience researchers with the tools they need to advance their research.

We also offer other related services, including but not limited to:

Services Descriptions
Custom Neural Differentiation As experienced experts in neuroscience modeling, we offer comprehensive customized neural differentiation services to effectively support your neuroscience research.
High-efficient Astrocyte Differentiation Technology We have a well-established differentiation platform to rapidly and efficiently generate human astrocytes of high quality in terms of morphology, molecular profile and function.
STEMOD™ Advanced Drug Discovery We have developed a comprehensive technology platform to provide one-stop CNS drug discovery services. Our platform has advanced neuroscience ex vivo models, neuroscience assay techniques, and neuroscience research tools.

Applications of Reprogramming Factors in Neuroscience Research

By using advanced reprogramming factors, we enable researchers to generate, maintain, and study neuronal cell types and their interactions with unprecedented precision. This service supports a wide range of applications in understanding neural development, CNS disease modeling, and therapeutic discovery.

  • To produce specific types of neurons from PSCs or other non-neuronal cells
  • To create cellular models of neurological disorders
  • To investigate the differentiation pathways and mechanisms of neural progenitors into mature neurons
  • To assess the functional properties of reprogrammed neurons
  • To evaluate the effects of pharmacological agents on neuronal cells
  • To study the role of specific genes in neuronal development and function
  • To explore how neurons interact and form networks
  • To develop patient-specific neuronal models

For more information or to discuss your specific research needs, please contact us to explore how our reprogramming factors services can advance your neuroscience research.

FAQs

Q: What types of reprogramming factors do you offer for neuroscience research?

A: We offer a comprehensive range of reprogramming factors tailored for neuroscience research, including transcription factors such as Oct4, Sox2, Klf4, and c-Myc, as well as more specialized factors like Ascl1, Brn2, and Myt1l for neural reprogramming. Our factors are available in various formats, including plasmids, viral vectors, and proteins, to suit different experimental needs and preferences.

Q: Can your reprogramming factors be used with different cell types, or are they specific to certain cell lines?

A: Our reprogramming factors are versatile and can be used with a variety of cell types, including fibroblasts, astrocytes, and other somatic cells. While some factors may work more efficiently with specific cell types, we provide detailed protocols and recommendations to help you achieve optimal results regardless of the starting cell line. Our technical support team is also available to assist with any specific requirements or challenges you may encounter.

Q: Are your reprogramming factors compatible with both in vitro and in vivo applications?

A: Yes, our reprogramming factors are designed to be compatible with both in vitro and in vivo applications. For in vitro studies, they are optimized to efficiently reprogram cells in culture, while for in vivo experiments, they can be delivered directly into tissues or organisms. We provide guidelines for both types of applications, ensuring you can use our products effectively in your specific research setting.

Q: What delivery methods do you offer for your reprogramming factors, and how do they affect the efficiency of reprogramming?

A: We offer multiple delivery methods for our reprogramming factors, including viral vectors (e.g., lentivirus, retrovirus), non-viral vectors (e.g., plasmids, nanoparticles), and direct protein delivery. Each method has its advantages depending on the experimental context. Viral vectors typically provide high efficiency and stable integration, while non-viral methods offer transient expression with reduced genomic integration risks. Our team can help you choose the best delivery method for your specific needs.

Scientific Resources

Reference

  1. Prasad, A.; et al. A review of induced pluripotent stem cell, direct conversion by trans-differentiation, direct reprogramming and oligodendrocyte differentiation. Regenerative Medicine. 2016, 11(2), 181-191.

For Research Use Only. Not For Clinical Use.